409082-11-7

Basic information

• Product Name: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE
• Synonyms: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE;Benzeneacetonitrile, 2-Methyl-5-nitro-
• CAS NO: 409082-11-7
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.172
• Mol File: 409082-11-7.mol

Chemical Properties

• Boiling Point: 361.613 °C at 760 mmHg
• Flash Point: 172.498 °C
• Appearance: /
• Density: 1.226 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE(409082-11-7)
• EPA Substance Registry System: 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE(409082-11-7)

Safety Data

• Hazardous Substances Data: 409082-11-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-METHYL-5-NITROPHENYL)ACETONITRILE is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of a diverse range of compounds with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE is employed as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its involvement in the synthesis of these chemicals aids in the development of effective solutions for agricultural challenges.
Used in Organic Synthesis:
2-(2-METHYL-5-NITROPHENYL)ACETONITRILE is used as a building block in organic synthesis, enabling the creation of complex organic molecules with a wide range of applications. Its versatility in chemical reactions makes it a valuable component in the synthesis of various organic compounds.
Used in Research and Development:
In the field of research and development, 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE is utilized for studying its biological and pharmacological activities. Its derivatives are investigated for their potential applications in medicine and drug development, contributing to the advancement of scientific knowledge and the discovery of novel therapeutic agents.
It is crucial to handle 2-(2-METHYL-5-NITROPHENYL)ACETONITRILE with care, as it can be harmful if ingested or inhaled and may cause skin and eye irritation upon contact. Proper safety measures should be taken to minimize risks associated with its use.

Upstream product

• 77324-87-9 methyl 2-methyl-5-nitrobenzoate 
• 1975-52-6 5-nitro-o-toluic acid 
• 22474-47-1 (2-methyl-5-nitro-7-phenyl)methanol 
• 58966-24-8 2-(chloromethyl)-4-nitrotoluene 
• 773837-37-9 sodium cyanide 
• 409082-10-6 (2-methyl-5-nitrophenyl)-methyl methylsulfonate 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 287119-83-9 2-(2-Methyl-5-nitrophenyl)acetic acid 
• 1021535-31-8 3-(5-amino-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 850451-77-3 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 
• 1021532-47-7 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenylcarbamothioyl)benzamide 
• 1185281-07-5 3-(5-isothiocyanato-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185281-04-2 C₁₈H₁₆N₄O 
• 1185855-70-2 (E)-1-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenyl)-2-hydroxyguanidine 
• 1185281-06-4 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenyl)-1H-imidazole-1-carboxamide 
• 1185279-54-2 3-(5-(5-isopropyl-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185280-98-1 3-(5-(3-isopropyl-1,2,4-oxadiazol-5-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185281-08-6 N-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenylcarbamothioyl)isobutyramide 
• 1185280-85-6 3-(5-(5-cyclopropylisoxazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185279-51-9 3-(5-(5-cyclopropyl-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185280-06-1 3-(5-{[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]amino}-2-methylphenyl)-1,7-dimethyl-1,2-dihydro-1,6-naphthyridin-2-one 

Relevant articles and documents

(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.

Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: Variation of the central linker group

As part of our investigation into the pyrazolo[1,5-a]pyridines as novel PI3K inhibitors, we report a range of analogues where the central linker portion of the molecule was varied while retaining the pyrazolo[1,5-a]pyridine and arylsulfonyl or arylcarbonyl groups. Isostere generating software BROOD was used to assist with producing ideas. The isoform selectivity of the compounds varied from pan-PI3K for compound 41 to p110α-selective for compound 58 or p110δ-selective for compound 57. The latter two compounds varied only in their sulphur oxidation state.

HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR , PDGFR , CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF , SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2 , BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF beta , SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2 beta kinases.

Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compound